Minapharm Announces the Appointment of Dr. Alfred Merz, PhD as COO and Interim CEO of its Berlin-Based Subsidiary ProBioGen AG

Cairo, Berlin – May 30, 2024 - Minapharm, the leading pharmaceutical and biopharmaceutical company in Egypt, Africa, and the Middle East announced on May 30th, the appointment of Dr. Alfred Merz, PhD as the new COO and interim CEO of its Berlin-based subsidiary ProBioGen AG, a world leading Contract Development and Manufacturing Organization (CDMO) and technology provider with expertise in cell line engineering, process development, and GMP manufacturing.

Minapharm Pharmaceuticals and Cheerland Biotechnology Sign a Memorandum of Understanding towards a Strategic Partnership in the MEA Region and Asia

Cairo, Egypt – Shenzhen, China -- Dec 21.12.2023

Minapharm Pharmaceuticals, a premier biopharmaceutical company in the Middle East and Africa and global provider of proprietary technologies, headquartered in Egypt with multiple global subsidiaries, and Cheerland Biotechnology (CLB), a global biologics contract development and manufacturing organization based in China, today, December 21st, 2023, announced the signing of a Memorandum of Understanding (MoU) with the aim of jointly pursuing potential business opportunities in the MEA region and Asia.

Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the manufacture of Clexane®

Sanofi and Minapharm announce the signing of an exclusive Manufacturing and Supply Agreement for the localization of the full range of its flagship market leader product, Clexane®.

The agreement between Sanofi, a global pharmaceutical company and Egypt’s Minapharm, a regional Biotech company with wholly owned subsidiaries in Cairo and Berlin, boosts Egypt’s national localization strategy of biopharmaceutical manufacturing.

SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries

SaudiVax, a leading biopharmaceutical company in Saudi Arabia, Minapharm Pharmaceuticals, a premier biopharmaceutical company and global provider of proprietary technologies headquartered in Egypt with multiple subsidiaries in Berlin, and MiGenTra GmbH, a healthcare transforming medicines company headquartered in Berlin, today announced the signing on 26th September 2023 of a Memorandum of Understanding (MOU) for the companies to jointly pursue potential business opportunities in Saudi Arabia and the Gulf Cooperation Countries (Region). The partnership is intended to leverage the companies’ strengths, matching Minapharm’s and MiGenTra’s cutting-edge development and manufacturing technologies and translational experience of high-quality affordable bio-engineered products with SaudiVax’s industrial capabilities and commercial reach in the Region.

LEO Pharma & Minapharm sign an exclusive agreement in Egypt

LEO Pharma & Egypt’s Minapharm expand a longstanding strategic manufacturing partnership of three decades. The successful long-term brands Fucidin® and Fucicort® account for dominant market shares in their categories. The new agreement further adds commercialization of a full portfolio of innovative dermatologic therapeutics for treatment of psoriasis and atopic dermatitis to fulfill unmet medical needs of patients across Egypt.

Minapharm Pharmaceuticals receives regulatory approval from the Paul-Ehrlich Institute for a phase 1 multi-center clinical trial in Germany for its Adalimumab biosimilar

Cairo, February 13, 2023; Minapharm Pharmaceuticals and Chemical Industries S.A.E announced today the unconditional approval of a phase 1 clinical trial for its Adalimumab biosimilar through the Paul-Ehrlich Institute (PEI) and the responsible ethical committee. The product has been submitted for approval by the Egyptian health authorities and is expected to be marketed under the name Adessia.

The approved study is a multi-center, randomized, double-blind, 2-arm, parallel group trial in 154 healthy male and female participants. It compares the pharmacokinetics, safety, immunogenicity and tolerability of the Adalimumab biosimilar, Adessia, and its reference product Humira. First dosing will occur in February 2023 and results from the study are expected by the end of this year.

Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa

Bioventure, a Dubai-based pharmaceutical company, Minapharm Pharmaceuticals, a Cairo-based pharmaceutical company, and MiGenTra GmbH, a Berlin-based pharmaceutical company, announced today the signing of an exclusive license agreement for the commercialization of multiple biosimilar candidates developed and manufactured by Alvotech, in Egypt and eighteen additional countries in Africa and the Middle East (the "Territory").

Minapharm Pharmaceuticals Announces the Successful Completion of its Phase 1 Clinical Trial in Europe for its Recombinant Teriparatide, Bonosome.

Minapharm Pharmaceuticals announces the successful completion of the phase 1 clinical trial in Germany evaluating its Teriparatide Biosimilar, Bonosome, a recombinant formulation of endogenous parathyroid hormone (PTH) injection indicated for mild to severe osteoporosis. This achievement marks the first African biosimilar to succeed in a European clinical trial, with an aim to enhance African self-sustainability and provide innovative, quality and affordable medicines to the region.

ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company

ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant. The formation of MiGenTra accelerates ProBioGen's 2030 growth roadmap and showcases that further growth is not limited to the ongoing capacity increase but reveals one of several significant steps in the diversification of ProBioGen's business.

BioGaia Signs Exclusive Agreement in Egypt

BioGaia has signed an agreement with Minapharm Pharmaceuticals for the exclusive rights to sell BioGaia Protectis drops in Egypt. The probiotic will be sold under the BioGaia brand. Launch is planned to Q4 2021.

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

Moscow/Cairo/Berlin, April 22, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG announce the agreement to produce over 40 million doses per year of the world’s first registered vaccine against COVID-19, Sputnik V.

Minapharm Announces the First of its Kind Approval from the German Regulatory Authority BfArM to Conduct a Phase 1 Clinical Trial of a Biosimilar Developed in Egypt and the Region

Minapharm Pharmaceuticals S.A.E has announced today that the German regulatory authority BfArM (Federal Institute for Drugs and Medical Devices) approved a phase 1 clinical trial for its biosimilar teriparatide in Germany. The product has been submitted...

Minapharm Announces Appointment of Two New Board Members

Minapharm announced on July 27th 2020, the appointment of Dr. Shaheer Bardissi and Mr. Tarek Mounib as new members to the board of directors.

International Biotech Expert Dr. Lutz Hilbrich,
Now the CEO of ProBioGen AG

Minapharm pharmaceuticals, the leading biopharmaceutical company in Egypt, Africa and the Middle East, announced on June the 1st, the appointment of Dr. Lutz Hilbrich, an experienced biotech executive, as the new CEO of its Berlin-based subsidiary ProBioGen AG.

Minapharm's 2018 Summer Internship: A Great Success

Minapharm's summer internship for 2018 has concluded successfully after two great months of learning. The internship was offered from July till to early September ...

Minapharm Awarded as One of the Top Companies in Egypt

Minapharm was honored for its role as one of the 100 top companies operating in Egypt and one of the only two top pharmaceutical companies in 2017...

Our Subsidiary ProBioGen celebrates the 20th anniversary: €20 million investment in Mammalian Manufacturing Expansion

On the occasion of its 20th anniversary,ProBioGen AG announced to invest 20€ million and to double its workforce ...

VTU Technology, Austria and MINAPHARM Pharmaceuticals S.A.E., Egypt enter into development and license agreement

VTU Technology and MINAPHARM Pharmaceuticals announced today, that they have entered into a licensing agreement to develop a therapeutic, recombinant Human Serum Albumin (rHSA). Under the terms of the agreement, VTU Technology grants MINAPHARM access to VTU´s Pichia pastoris protein expression technology for rHSA production.

MINAPHARM Pharmaceuticals acquires majority stake in ProBioGen – Dr. Wieland Wolf appointed new CEO

ProBioGen AG announced today that MINAPHARM Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones. ProBioGen will continue to be a committed technology and service provider for its global biopharmaceutical clients. The company will also continue to develop proprietary technologies in the field of biopharmaceutical products.

Cyplasin Biomedical and Minapharm SAE announce Term Sheet Agreement for Distribution and Manufacture of Cyplasin Products

Cyplasin Biomedical (CPBM: OTCBB and XYI1:FRA) and Minapharnn SAE (Cairo and Alexandria Stock Exchange: MIPH) jointly announced the successful negotiation and signing of a binding term sheet agreement for the sales/marketing and distribution of Cyplasin's product C-Virin for use with chronically infected Hepatitis C patients within the Middle East and MENA regions. The agreement also encompasses the eventual manufacture and marketing of Cyplasin's future vaccine product C- Vaxin once it is available. The agreement further includes a small convertible debt loan from Minapharm to Cyplasin which will be used for initial manufacturing setups.

ARTES and Rhein MINAPHARM continue their successful product development collaboration

Langenfeld and Cairo, November 16, 2009 / b3c newswire / – ARTES Biotechnology, specialized in recombinant protein production and process development from yeast expression systems, and Rhein MINAPHARM Biogenetics, a subsidiary of MINAPHARM S.A.E. (Cairo and Alexandria Stock Exchange: MIPH) jointly announced the successful production of a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009.

MINAPHARM CEO WELCOMES THE PRESIDENT OF THE REPUBLIC OF RWANDA AT AFRICA’S ONLY GENE-TO-MARKET BIOPHARMACEUTICAL COMPANY IN EGYPT AND THE MIDDLE EAST

During his 4 day state visit to Egypt, Rwanda president Paul Kagame and a political delegation payed an attendance to Minapharm Pharmaceuticals. He was accompanied by the Egyptian Minister for Agriculture Mr. Amen Abaza.

PolyTherics and Minapharm Pharmaceuticals sign Collaboration Agreement to create enhanced biopharmaceuticals

PolyTherics Limited (“PolyTherics”), the biopharmaceuticals company dedicated to precision engineering of proteins to improve their pharmacokinetic properties, today announced the initiation of a research collaboration agreement with Minapharm Pharmaceuticals the leading Egyptian pharmaceutical company. PolyTherics will apply its proprietary drug modification technologies to a target

Rhein Minapharm and ProBioGen announce additional cell line development agreement

Berlin, December 16, 2008 – Rhein Minapharm Biogenetics SAE and ProBioGen today announced that they have closed their third cell line development agreement. The agreement covers the development of a second generation interferon-β compound with high economic potential and adds to the first two collaboration contracts signed in early 2007.

Proteo Inc./Proteo Biotech AG – Minapharm/Rhein Minapharm Biogenetics SAE: Approval for a Phase II clinical trial with Elafin in kidney transplantation

Irvine, CA – Kiel – Cairo, 10th December 2008 – Proteo, Inc. (OTCBB: PTEO; Frankfurt Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG together with Minapharm Pharmaceuticals SAE (Cairo and Alexandria Stock Exchange: MIPH) and its subsidiary Rhein Minapharm Biogenetics

ARTES and Minapharm sign long-term strategic development agreement

Langenfeld and Cairo, January 14, 2008 / b3c newswire / – ARTES Biotechnology, which is specialized in recombinant protein production from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE (Cairo and Alexandria Stock Exchange: MIPH) jointly

Minapharm and BankInvest Private Equity New Markets (BankInvest) enter into financial partnership.

Cairo and Copenhagen, 10th December 2007 – Minapharm Pharmaceuticals (Egypt) and BankInvest (Denmark) announced today that they signed an agreement through which BankInvest will

Proteo Biotech, Germany and Minapharm, Egypt enter into development and license agreement for Elafin

Irvine, CA – Kiel – Cairo, August 9, 2007 – Proteo, Inc. (OTCBB: PTEO; Frankfurt Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG together with Minapharm Pharmaceuticals SAE (Cairo and Alexandria Stock Exchange: MIPH) and its subsidiary Rhein Minapharm Biogenetics SAE announced today:

ProBioGen, Germany and Minapharm, Egypt enter into development and co-promotion agreements

Berlin and Cairo, 19 April 2007 – ProBioGen and Minapharm jointly announced today that they have entered into two separate agreements to develop two therapeutic proteins

Minapharm / Pierre Fabre Medicament Ossopan 800 Launching Training

To ensure Minapharms~ multi-alliance policy; Minapharm / Pierre Fabre Medicament has organised the launching training of Ossopan 800.

All of Us at Minapharm Congratulate Our CEO!

In a memorable celebration, Dr. Saad El-Bardissi was acknowledged by the Syndicate of Pharmacists as the “Dean of Pharmacists” for this year in Egypt. The medal award was presented by the Minister of Health and Population Dr. Mohamed Awad Tag El-Din and the Minister of Labour Mr. Ahmed El-Amawy

Rhein Minapharm introduces the 1st Biogenetics Line in the Middle East

In accordance to Minapharm’s mission in providing innovative quality products to patients in developing countries, Minapharm established a joint venture with Rhein Biotech Germany, “Rhein Minapharm”. This joint venture is based on Rhein Biotech’s technological expertise and Minapharm’s marketing and pharmaceutical experience.

Another strategic alliance for Minapharm

On 28th June, 2004, Minapharm signed a license manufacturing agreement with Hexal AG to manufacture 25 products of different pharmaceutical forms. This cooperation introduces a new segment in the Egyptian market: brand generics. Brand generics are bioequivalent copies of original drugs but carry a brand name.

ARTIFICIAL INTELLIGENCE confirms:

ARTIFICIAL INTELLIGENCE confirms: Minapharm~s Organisational Innovations at the forefront

Minapharm Goes Public:

Minapharm Pharmaceuticals & Chemical Industries announced to shareholders that the company’s shares are now registered as of December 21, 2003 in the CENTRAL DEPOSITORY OF THE MISR FOR CLEARING SETTLEMENT & DEPOSITORY.

We are changing our package

Our commitment to offer better service to patients and physicians is the reason for

Rhein Minapharm signs joint research agreement with Rephartox

Rhein Minapharm Biogenetics signed a joint research agreement with Rephartox to develop three new vaccine formulations

Minapharm participation in the Farewell of Mr. Paul Derks

MINAPHARM participated in the farewell party of Mr. Paul Derks, Country Manager, Janssen-Cilag, Egypt

Praxilene Training

Minapharm~s marketing team was gathered at Palmera Resort, Ein El-Sokhna to attend a special training course on Praxilene

Minapharm Marketing Team gathering for refreshment training

In the continuation of Minapharm/ OM Pharma~s mutual cooperation in the scientific field, Minapharm organized with OM Pharma a refreshing training for its marketing and scientific teams in Egypt